SAN DIEGO--Genta Incorporated's antisense oligonucleotide targeted
against the BCL-2 gene has proved effective against drug-resistant
cancers in certain animal models of follicular lymphoma and colon
cancer, the company said.
The BCL-2 gene is overexpressed in many tumors, preventing normal
apoptosis and inducing drug resistance. A phase I/II trial in
drug-resistant follicular lymphoma is scheduled to begin at The
Royal Marsden Hospital, London, by mid-year.